Malignant Mesothelioma
- Pleural, Peritoneal & Pericardial
Malignant
Mesothelioma Explained
Malignant mesothelioma is a rare form of cancer that is diagnosed in
approximately 3,000 people each year. The disease usually affects the
pleura, which is the membrane that lines the chest cavity and the lungs.
It may also affect the peritoneum, which is the lining of the abdominal
cavity, and (very rarely) the pericardium, which is the lining around
the heart. The pleura, peritoneum and pericardium each have two layers,
which are separated by a lubricating fluid that allows the internal
organs to move easily. About 70 percent of all cases of malignant mesothelioma
can be attributed to exposure to asbestos, a naturally occurring mineral
that is used in a variety of industries. A small percentage of the remaining
cases have been linked to exposure to a particular type of radiation
or to a mineral silicate called zeolite. In some cases, the cause is
unknown.
People exposed to
asbestos for a long time or exposed to high levels have an increased risk
of developing malignant mesothelioma, but even people exposed for a very
short time can develop this disease. The disease occurs a minimum of 15
years (typically 20 to 40 years) after asbestos exposure. The average
age at diagnosis is 50 to 70 years. More men than women are affected,
probably because men are more likely to have worked in the industries
that use asbestos.
Three main types
of malignant mesothelioma are recognized: epithelial, sarcomatoid and
mixed. The epithelial type is the most common. All three types have the
same treatment options.
Malignant
Mesothelioma Symptoms
About 90 percent of patients who are diagnosed with malignant mesothelioma
have chest pain and shortness of breath as the first symptoms of the disease.
These symptoms are generally caused by pleural effusion (collection of
fluid in the chest), not by mesothelioma itself. Individuals with mesothelioma
that originates in the peritoneum (abdominal lining) may have abdominal
pain and swelling due to an accumulation of fluid in the abdominal cavity.
Other possible symptoms include fever, sweating, cough, fatigue and unexplained
weight loss.
Malignant
Mesotheloima Diagnosis
Diagnosis of malignant mesothelioma begins with a thorough medical history
to document the patient's symptoms and any possible asbestos exposure,
followed by a complete physical examination. These steps are generally
followed by a chest or abdominal X-ray, computed tomography or magnetic
resonance imaging . The imaging studies allow the physician to assess
the size, location and extent of the tumor in the chest or abdomen.
If fluid
is present in the pleura or peritoneum, a thin needle may be used to collect
a small sample of the fluid for examination (this procedure is called
fine-needle aspiration). This technique may also be used to drain the
fluid to relieve symptoms such as chest pain and shortness of breath that
can result from an effusion. Occasionally, mesothelioma can be diagnosed
with this fluid sample alone, but usually a tissue sample (biopsy) is
required. The tissue sample can be obtained with a long needle via thoracoscopy
(for a pleural tumor) or via laparoscopy (for an abdominal tumor). In
both procedures, a tubelike instrument inserted through a small incision
allows the physician to view the tumor and collect a tissue sample. Patients
suspected of having pleural mesothelioma may also need a procedure called
bronchoscopy .
If a larger sample
of tissue is needed, a surgeon may open the chest cavity (called thoracotomy)
or the abdominal cavity (called laparotomy).
Staging
of Malignant Mesothelioma
Once the diagnosis
of malignant mesothelioma has been confirmed, the next step is determining
the extent of the disease (called staging). Imaging studies, such as computed
tomography and magnetic resonance imaging, allow physicians to assess
the stage of the disease and determine the most appropriate treatment.
The Butchart stages of malignant mesothelioma are:
Mesothelioma
Stage I - The tumor is found in the pleura with or without some
involvement of the lung, pericardium (lining of the heart) or diaphragm.
Mesothelioma Stage II - The tumor is found in a stage
I location, plus there is involvement of some lymph nodes in the chest.
Mesothelioma Stage III - The tumor has extended into
the chest wall, ribs or heart, through the diaphragm or into the peritoneum
(the abdominal lining). There may also be involvement of the lymph nodes.
Mesothelioma Stage IV - The tumor has spread through
the bloodstream to distant sites (that is, it has metastasized).
Recurrent Mesothelioma - The tumor has recurred after
treatment.
Stage I is also called localized disease, whereas stages
II to IV are called advanced disease. Stage I disease generally has the
best prognosis, particularly when the tumor is of the epithelial type
and the patient is younger than 55.
Mesothelioma
Prevention
To reduce your risk of malignant mesothelioma, you should reduce your
exposure to asbestos. Because there is no "safe" level of asbestos
exposure, any asbestos exposure is too much. Especially if you have an
older home, check for areas of exposed asbestos-containing insulation
or other areas of deteriorating asbestos. These areas must be professionally
removed or safely sealed off. Workers who routinely deal with asbestos-containing
materials should use approved measures to limit their exposure and to
keep from bringing asbestos dust home on their clothing.
Medical
Treatment of Malignant Mesothelioma
The treatment of malignant mesothelioma has proven difficult. Because
the disease begins in the pleura and peritoneum, which are the membranes
surrounding the chest cavity and abdominal cavity, respectively, mesothelioma
almost always spreads to the underlying organs. The tumor spread makes
complete surgical removal nearly impossible. Furthermore, the effectiveness
of different treatments has been difficult to evaluate in large treatment
trials because there are relatively few cases of malignant mesothelioma.
Although the general
prognosis for malignant mesothelioma is not encouraging - on average,
patients live about one year after diagnosis - an early diagnosis and
aggressive treatment can improve survival - up to 2 years in almost 50
percent of cases and five years (or longer) in 20 percent. Some of the
factors that affect prognosis are the type of mesothelioma, the stage
of disease at diagnosis, the patient's age and the patient's overall health.
The prognosis is best when the mesothelioma is the epithelial type and
stage I and the patient is younger than 55 and does not have an underlying
illness.
Types of
Available Medical Treatment, Drug Therapy, Chemotherapy and Surgery for
Malignant Mesothelioma Victims
The primary treatment
options for malignant mesothelioma are surgery, radiation therapy and
chemotherapy.
Surgery — Before any surgery is considered for the treatment of malignant
mesothelioma, the patient's overall health is carefully evaluated. Tests
are performed to make sure the patient has no metastatic disease (cancer
spread to distant sites) and to evaluate the patient's pulmonary (lung)
and cardiac (heart) function. Pulmonary function is often compromised
in patients with pleural mesothelioma for several reasons. The pleural
effusion (fluid collection) and the tumor mass caused by mesothelioma
can compress the lung. Also, the patient's exposure to asbestos may have
decreased lung function, which also decreases with age. In addition, some
patients have a history of smoking cigarettes, which further decreases
lung function.
Surgery for malignant
mesothelioma may be aimed at cure (aggressive surgery) or relief of symptoms
(palliative procedures).
Aggressive
surgery - Extrapleural pneumonectomy involves removal of the
pleura, the lung, the diaphragm and the pericardium. The intent of this
very aggressive, complicated surgery is to remove as much of the tumor
as possible. Not all centers will perform this procedure because of its
complexity and because it carries a high risk of postoperative mortality
(death within 30 days after surgery). Extrapleural pneumonectomy is typically
performed only in younger patients in good overall health with stage I
disease. Patients are evaluated carefully to determine their ability to
tolerate the surgery. Palliative procedures - When malignant mesothelioma
is advanced, palliative procedures may be performed to relieve and/or
control symptoms such as breathlessness and pain, which are caused by
effusion (fluid collection) or by the tumor compressing the lung or other
organs. These procedures do not aim to cure the disease.
Thoracentesis may
be used to treat effusion in pleural mesothelioma. A needle is inserted
into the chest to drain the fluid, relieving breathlessness and pain.
Talc may be introduced into the pleura to prevent recurrence of the effusion.
Similar procedures are used to treat ascites (fluid collection) in peritoneal
mesothelioma.
Pleurectomy / decortication
is the surgical removal of the pleura. This procedure may be performed
to reduce pain caused by the tumor mass or to prevent the recurrence of
pleural effusion. For peritoneal mesothelioma, surgery is generally aimed
at relieving symptoms, such as recurrent ascites or bowel obstruction.
As with pleural mesothelioma, complete surgical removal of the entire
tumor is unlikely.
Radiation Therapy - Mesothelioma
Because of the location
of malignant mesothelioma, it is extremely difficult to deliver high enough
doses of radiation to kill the tumor without damaging the surrounding
organs. Lower doses of radiation may result in some reduction in the disease,
but it is unclear whether this reduction actually results in longer survival
than does no treatment.
Using radiation
therapy after surgery has not been shown to improve survival. However,
because surgery is very unlikely to remove the entire tumor, radiation
is commonly administered after surgery in the hopes of killing remaining
tumor cells. In addition, radiation therapy can be used to relieve symptoms
of mesothelioma, including pain and shortness of breath.
Chemotherapy
- Mesothelioma
Chemotherapy - the use of medications to treat cancer - has had disappointing results
in the treatment of malignant mesothelioma. Some chemotherapy drugs have
a partial effect in some patients. Combination chemotherapy (using more
than one drug at the same time) may be given in an attempt to improve
response. Some combinations have shown some promise, and some new medications
are being tried.
Like radiation therapy,
chemotherapy may be administered after surgery in an attempt to kill cancer
cells that could not be removed during the procedure.
Treatment
by Mesothelioma Stage
Pleural mesothelioma
can be treated according to stage; there are no standard treatment options
by stage for peritoneal mesothelioma.
Stage I (localized) mesothelioma - If a patient wants aggressive treatment and
is deemed fit to undergo surgery, some centers may perform an extrapleural
pneumonectomy. Another surgical option is pleurectomy/decortication, which
is sometimes performed to alleviate some of the symptoms of mesothelioma.
Both of these procedures may be followed by radiation therapy or chemotherapy.
Alternatively, radiation therapy may be used alone, without surgery, for
the relief of symptoms.
Stages II,
III and IV (advanced) mesothelioma - Pleurectomy/decortication
may be performed to relieve symptoms in pleural mesothelioma. Other procedures
such as thoracentesis may be performed to drain pleural effusions and
prevent them from recurring. Radiation therapy and/or chemotherapy may
also be administered for symptom relief.
Recurrent
malignant mesothelioma - There is no standard treatment for recurrent
mesothelioma; generally, treatments are chosen that were not used in the
first treatment attempt.
Clinical
Trials And Future Treatments
New treatments for
malignant mesothelioma (and possible preventive measures, such as a vaccine)
are being evaluated in clinical trials, and the future holds some promise.
Clinical trials are research studies that evaluate new treatments for
safety and effectiveness. There are no guarantees that a new treatment
will work, and there are some risks; however, a clinical trial is not
undertaken unless the researchers believe the treatment may have some
value.
Here are some of
the treatments for malignant mesothelioma that are being evaluated:
Combination
chemotherapy for mesothelioma - Different combinations of chemotherapy
drugs have been tried with mixed results. A recent study showed some benefit
of combining cisplatin and gemcitabine. The researchers used the combination
to treat 21 patients with advanced mesothelioma, of whom 47 percent showed
a partial response.
Medications
& Mesothelioma - One study showed that lovastatin, a cholesterol-lowering
drug, may be useful for the treatment of malignant mesothelioma. The drug
was found to induce apoptosis (cell death) in mesothelioma cells, which
may increase the effectiveness of radiation therapy and chemotherapy.
Intracavitary
Chemotherapy for Mesothelioma - Instilling chemotherapy drugs
directly into the pleural or peritoneal space is being researched because
of its advantage over traditional chemotherapy: because the drug is instilled
directly into the cavity, much greater doses can be given to patients
without causing severe side effects. Some studies have shown this therapy
to result in control of effusions and reduced tumor size.
Brachytherapy (intracavitary
radiation therapy) - In this treatment, a radioactive substance is placed
directly into the pleural or peritoneal space.
Multimodality
therapy - Any combination of surgery, radiation therapy and chemotherapy
is multimodality therapy. For example, researchers have combined surgery
with intracavitary radiation or chemotherapy and then administered radiation
or chemotherapy afterward. Some physicians are administering chemotherapy
before surgery in an attempt to decrease the size of the tumor.
Gene therapy
& Mesothelioma - In this approach, a virus that has been
genetically altered is introduced into the tumor. The virus infects the
tumor cells and makes them vulnerable to anticancer drugs.
Immunotherapy - Treatments that stimulate the body's immune system to fight cancer cells
are called immunotherapy.
Photodynamic
therapy - In this treatment, drugs that are sensitive to light
are taken up by the tumor cells, which are then exposed to light.
When To Call Your Doctor
Call your doctor promptly if you have any of the symptoms of lung cancer,
especially if you have worked in an industry with high exposure to asbestos.
Prognosis
Malignant mesothelioma is usually advanced by the time it is diagnosed
and thus has a poor prognosis: on average, the survival time after diagnosis
is about one year. However, several factors affect prognosis, including
the extent of the tumor and the age and health of the patient. In some
cases, survival time can be increased with early detection and aggressive
treatment, and improved treatments should be available in the near future.
Additional Information
and Links for Malignant Mesothelioma
For more information about lung cancer, you can contact:
National Cancer
Institute (NCI)
Building 31, Room 10A03
31 Center Drive, MSC 2580
Bethesda, MD 20892-2580
Phone: (800) 4-CANCER
Phone: (301) 435-3848
www.nci.nih.gov
American Cancer
Society
1599 Clifton Road, N.E.
Atlanta, GA 30329-4251
Phone: (800) ACS-2345
www.cancer.org
American Lung Association
National Office
1740 Broadway
New York, NY 10019
Phone: (800) LUNG-USA
www.lungsusa.org
The National Heart,
Lung and Blood Institute
6701 Rockledge Drive
P.O. Box 30105
Bethesda, MD 20824-0105
Phone: (301) 592-8573
NHLBIinfo@rover.nhlbi.nih.gov
www.nhlbi.nih.gov
U.S. Environmental
Protection Agency (EPA)
401 M Street, SW
Washington, DC 20460-0003
Phone: (202) 260-2090
www.epa.gov
If you work with
asbestos, you can access the website of the National Institute for Occupational
Safety and Health (NIOSH) for more information about protecting yourself
and your family. The NIOSH is part of the federal government's Centers
for Disease Control and Prevention (CDC).
National Institute
for Occupational Safety and Health
Address line 2
Phone: (800) 35-NIOSH
Fax: (513)533-8573
www.cdc.gov/niosh
|